- Home
- NPKI vs KROS Comparison
NPKI vs KROS Comparison
Compare NPKI & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPKI
- KROS
- Stock Information
- Founded
- NPKI 1932
- KROS 2015
- Country
- NPKI United States
- KROS United States
- Employees
- NPKI N/A
- KROS N/A
- Industry
- NPKI Metal Fabrications
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- NPKI Industrials
- KROS Health Care
- Exchange
- NPKI Nasdaq
- KROS Nasdaq
- Market Cap
- NPKI 621.1M
- KROS 460.6M
- IPO Year
- NPKI N/A
- KROS 2020
- Fundamental
- Price
- NPKI $6.85
- KROS $11.00
- Analyst Decision
- NPKI
- KROS Buy
- Analyst Count
- NPKI 0
- KROS 11
- Target Price
- NPKI N/A
- KROS $45.33
- AVG Volume (30 Days)
- NPKI 385.2K
- KROS 2.1M
- Earning Date
- NPKI 02-19-2025
- KROS 02-26-2025
- Dividend Yield
- NPKI N/A
- KROS N/A
- EPS Growth
- NPKI N/A
- KROS N/A
- EPS
- NPKI N/A
- KROS N/A
- Revenue
- NPKI $748,372,000.00
- KROS $651,000.00
- Revenue This Year
- NPKI N/A
- KROS $303.27
- Revenue Next Year
- NPKI N/A
- KROS N/A
- P/E Ratio
- NPKI N/A
- KROS N/A
- Revenue Growth
- NPKI 93.70
- KROS 8037.50
- 52 Week Low
- NPKI $5.61
- KROS $9.78
- 52 Week High
- NPKI $8.65
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- NPKI N/A
- KROS 24.79
- Support Level
- NPKI N/A
- KROS $11.04
- Resistance Level
- NPKI N/A
- KROS $11.99
- Average True Range (ATR)
- NPKI 0.00
- KROS 0.60
- MACD
- NPKI 0.00
- KROS 1.20
- Stochastic Oscillator
- NPKI 0.00
- KROS 43.99
About NPKI NPK International Inc. Common Stock
NPK International Inc Formerly Newpark Resources Inc is a diversified supplier providing environmentally-sensitive products, as well as rentals and services to customers across multiple industries. The company has two operating segments: Industrial Solutions and Fluids Systems. Fluids Systems segment which generates the majority of the revenue, provides drilling, completion, and stimulation fluids products and related technical services to customers for oil, natural gas, and geothermal projects. Geographically, the company derives majority of its revenue from the United States and also has its presence in Canada, EMEA, Latin America, and Asia Pacific regions.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.